Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA

Science Translational Medicine

Volumn 3, Issue 94, 2011, Pages

  Tomlins, Scott A ^a   Aubin, Sheila M J ^b   Siddiqui, Javed ^a   Lonigro, Robert J ^a   Sefton Miller, Laurie ^a   Miick, Siobhan ^b   Williamsen, Sarah ^b   Hodge, Petrea ^b   Meinke, Jessica ^b   Blase, Amy ^b   Penabella, Yvonne ^b   Day, John R ^b   Varambally, Radhika ^a   Han, Bo ^a   Wood, David ^a   Wang, Lei ^a   Sanda, Martin G ^c   Rubin, Mark A ^d   Rhodes, Daniel R ^a   Hollenbeck, Brent ^a   Sakamoto, Kyoko ^e   Silberstein, Jonathan L ^e   Fradet, Yves ^f   Amberson, James B ^g   Meyers, Stephanie ^a   Palanisamy, Nallasivam ^a   Rittenhouse, Harry ^b   Wei, John T ^a   Groskopf, Jack ^b   Chinnaiyan, Arul M ^a   more..

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Gen Probe Incorporated   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITÉ LAVAL   (Canada)

^g Dianon Systems   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG; TRANSMEMBRANE PROTEASE SERINE 2; UNCLASSIFIED DRUG; MESSENGER RNA; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SIZE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; GENETIC ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INVASIVE MEASUREMENT; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; URINALYSIS; BIOPSY; BLOOD; COHORT ANALYSIS; GENETICS; MIDDLE AGED; PROSTATE TUMOR; RISK ASSESSMENT; URINE;

AGED; BIOPSY; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79961222799     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001970     Document Type: Article

References (43)

1. L. E. Ross, Z. Berkowitz, D. U. Ekwueme, Use of the prostate-specific antigen test among U.S. men: Findings from the 2005 National Health Interview Survey. Cancer Epidemiol. Biomarkers Prev. 17, 636-644 (2008).
2. R. L. Grubb III, P. F. Pinsky, R. T. Greenlee, G. Izmirlian, A. B. Miller, T. P. Hickey, T. L. Riley, J. E. Mabie, D. L. Levin, D. Chia, B. S. Kramer, D. J. Reding, T. R. Church, L. A. Yokochi, P. A. Kvale, J. L.Weissfeld, D. A. Urban, S. S. Buys, E. P. Gelmann, L. R. Ragard, E. D. Crawford, P. C. Prorok, J. K. Gohagan, C. D. Berg, G. L. Andriole, Prostate cancer screening in the Prostate, Lung, Colorectal andOvarian cancer screening trial: Update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 102, 1524-1530 (2008).
3. F. H. Schröder, J. Hugosson, M. J. Roobol, T. L. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Berenguer, L. Määttänen, C. H. Bangma, G. Aus, A. Villers, X. Rebillard, T. van der Kwast, B. G. Blijenberg, S. M. Moss, H. J. de Koning, A. Auvinen; ERSPC Investigators, Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328 (2009).
4. M. S. Lucia, A. K. Darke, P. J. Goodman, F. G. La Rosa, H. L. Parnes, L. G. Ford, C. A. Coltman Jr., I. M. Thompson, Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: Implications for prostate cancer detection and chemoprevention. Cancer Prev. Res. 1, 167-173 (2008).
5. I.M. Thompson, D. K. Pauler, P. J. Goodman, C.M. Tangen, M. S. Lucia, H. L. Parnes, L. M.Minasian, L. G. Ford, S. M. Lippman, E. D. Crawford, J. J. Crowley, C. A. Coltman Jr., Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350, 2239-2246 (2004).
6. I.M. Thompson, D. P. Ankerst, C. Chi, P. J.Goodman, C. M. Tangen, M. S. Lucia, Z. Feng, H. L. Parnes, C. A. Coltman Jr., Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 98, 529-534 (2006).
7. G. Draisma, R. Etzioni, A. Tsodikov, A. Mariotto, E. Wever, R. Gulati, E. Feuer, H. de Koning, Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J. Natl. Cancer Inst. 101, 374-383 (2009).
8. G. L. Andriole, E. D. Crawford, R. L. Grubb III, S. S. Buys, D. Chia, T. R. Church, M. N. Fouad, E. P. Gelmann, P. A. Kvale, D. J. Reding, J. L. Weissfeld, L. A. Yokochi, B. O'Brien, J. D. Clapp, J. M. Rathmell, T. L. Riley, R. B. Hayes, B. S. Kramer, G. Izmirlian, A. B. Miller, P. F. Pinsky, P. C. Prorok, J. K. Gohagan, C. D. Berg; PLCO Project Team, Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009).
9. S. A. Strope, G. L. Andriole, Prostate cancer screening: Current status and future perspectives. Nat. Rev. Urol. 7, 487-493 (2010).
10. F. H. Jansen, M. Roobol, G. Jenster, F. H. Schröder, C. H. Bangma, Screening for prostate cancer in 2008 II: The importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur. Urol. 55, 563-574 (2009).
11. R. J. Leary, I. Kinde, F. Diehl, K. Schmidt, C. Clouser, C. Duncan, A. Antipova, C. Lee, K. McKernan, F. M. De La Vega, K. W. Kinzler, B. Vogelstein, L. A. Diaz Jr., V. E. Velculescu, Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2, 20ra14 (2010).
12. S. A. Tomlins, D. R. Rhodes, S. Perner, S. M. Dhanasekaran, R. Mehra, X. W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J. E. Montie, R. B. Shah, K. J. Pienta, M. A. Rubin, A. M. Chinnaiyan, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
13. S. A. Tomlins, A. Bjartell, A. M. Chinnaiyan, G. Jenster, R. K. Nam, M. A. Rubin, J. A. Schalken, ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur. Urol. 56, 275-286 (2009).
14. B. Furusato, S. H. Tan, D. Young, A. Dobi, C. Sun, A. A. Mohamed, R. Thangapazham, Y. Chen, G. McMaster, T. Sreenath, G. Petrovics, D. G. McLeod, S. Srivastava, I. A. Sesterhenn, ERG oncoprotein expression in prostate cancer: Clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 13, 228-237 (2010).
15. K. Park, S. A. Tomlins, K. M. Mudaliar, Y. L. Chiu, R. Esgueva, R. Mehra, K. Suleman, S. Varambally, J. C. Brenner, T. MacDonald, A. Srivastava, A. K. Tewari, U. Sathyanarayana, D. Nagy, G. Pestano, L. P. Kunju, F. Demichelis, A. M. Chinnaiyan, M. A. Rubin, Antibody-based detection of ERG rearrangement- positive prostate cancer. Neoplasia 12, 590-598 (2010).
16. B. Han, R. Mehra, R. J. Lonigro, L. Wang, K. Suleman, A. Menon, N. Palanisamy, S. A. Tomlins, A. M. Chinnaiyan, R. B. Shah, Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod. Pathol. 22, 1083-1093 (2009).
17. B. S. Carver, J. Tran, A. Gopalan, Z. Chen, S. Shaikh, A. Carracedo, A. Alimonti, C. Nardella, S. Varmeh, P. T. Scardino, C. Cordon-Cardo, W. Gerald, P. P. Pandolfi, Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624 (2009).
18. J. M. Mosquera, S. Perner, E. M. Genega, M. Sanda, M. D. Hofer, K. D. Mertz, P. L. Paris, J. Simko, T. A. Bismar, G. Ayala, R. B. Shah, M. Loda, M. A. Rubin, Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin. Cancer Res. 14, 3380-3385 (2008).
19. Y. Zong, L. Xin, A. S. Goldstein, D. A. Lawson, M. A. Teitell, O. N. Witte, ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc. Natl. Acad. Sci. U.S.A. 106, 12465-12470 (2009).
20. J. C. King, J. Xu, J. Wongvipat, H. Hieronymus, B. S. Carver, D. H. Leung, B. S. Taylor, C. Sander, R. D. Cardiff, S. S. Couto, W. L. Gerald, C. L. Sawyers, Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524-526 (2009).
21. M. J. Bussemakers, A. van Bokhoven, G. W. Verhaegh, F. P. Smit, H. F. Karthaus, J. A. Schalken, F. M. Debruyne, N. Ru, W. B. Isaacs, DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975-5979 (1999).
22. I. L. Deras, S. M. Aubin, A. Blase, J. R. Day, S. Koo, A. W. Partin, W. J. Ellis, L. S. Marks, Y. Fradet, H. Rittenhouse, J. Groskopf, PCA3: A molecular urine assay for predicting prostate biopsy outcome. J. Urol. 179, 1587-1592 (2008).
23. J. Groskopf, S. M. Aubin, I. L.Deras, A. Blase, S. Bodrug, C. Clark, S. Brentano, J. Mathis, J. Pham, T. Meyer, M. Cass, P. Hodge, M. L. Macairan, L. S. Marks, H. Rittenhouse, APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 52, 1089-1095 (2006).
24. D. Hessels, F. P. Smit, G. W. Verhaegh, J. A. Witjes, E. B. Cornel, J. A. Schalken, Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13, 5103-5108 (2007).
25. B. Laxman, D. S. Morris, J. Yu, J. Siddiqui, J. Cao, R. Mehra, R. J. Lonigro, A. Tsodikov, J. T. Wei, S. A. Tomlins, A. M. Chinnaiyan, A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68, 645-649 (2008).
26. B. Laxman, S. A. Tomlins, R. Mehra, D. S. Morris, L. Wang, B. E. Helgeson, R. B. Shah, M. A. Rubin, J. T. Wei, A. M. Chinnaiyan, Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8, 885-888 (2006).
27. J. Nilsson, J. Skog, A. Nordstrand, V. Baranov, L. Mincheva-Nilsson, X. O. Breakefield, A. Widmark, Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br. J. Cancer 100, 1603-1607 (2009).
28. K. Rostad, O. J. Hellwinkel, S. A. Haukaas, O. J. Halvorsen, A. M. Oyan, A. Haese, L. Budaus, H. Albrecht, L. A. Akslen, T. Schlomm, K. H. Kalland, TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 117, 575-582 (2009).
29. F. Dong, J. S. Jones, A. J. Stephenson, C. Magi-Galluzzi, A. M. Reuther, E. A. Klein, Prostate cancer volume at biopsy predicts clinically significant upgrading. J. Urol. 179, 896-900 (2008).
30. S. F. Shariat, P. I. Karakiewicz, C. G. Roehrborn, M. W. Kattan, An updated catalog of prostate cancer predictive tools. Cancer 113, 3075-3099 (2008).
31. A. J. Vickers, E. B. Elkin, Decision curve analysis: A novel method for evaluating prediction models. Med. Decis. Making 26, 565-574 (2006).
32. F. K. Chun, A. Briganti, M. Graefen, F. Montorsi, C. Porter, V. Scattoni, A. Gallina, J. Walz, A. Haese, T. Steuber, A. Erbersdobler, T. Schlomm, S. A. Ahyai, E. Currlin, L. Valiquette, H. Heinzer, P. Rigatti, H. Huland, P. I. Karakiewicz, Development and external validation of an extended 10-core biopsy nomogram. Eur. Urol. 52, 436-444 (2007).
33. G. P. Haas, N. B. Delongchamps, R. F. Jones, V. Chandan, A. M. Serio, A. J. Vickers, M. Jumbelic, G. Threatte, R. Korets, H. Lilja, G. de la Roza, Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence. J. Natl. Cancer Inst. 99, 1484-1489 (2007).
34. N. B. Delongchamps, G. de la Roza, R. Jones, M. Jumbelic, G. P. Haas, Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int. 103, 49-54 (2009).
35. C. Gosselaar, M. J. Roobol, F. H. Schröder, Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: Aggressive or insignificant? BJU Int. 95, 231-237 (2005).
36. G. Attard, A. H. Reid, T. A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, J. Clark, C. S. Cooper, S. B. Kaye, D. Dearnaley, G. Lee, J. S. de Bono, Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571 (2008).
37. J. M. Mosquera, R. Mehra, M. M. Regan, S. Perner, E. M. Genega, G. Bueti, R. B. Shah, S. Gaston, S. A. Tomlins, J. T. Wei, M. C. Kearney, L. A. Johnson, J. M. Tang, A. M. Chinnaiyan, M. A. Rubin, M. G. Sanda, Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 15, 4706-4711 (2009).
38. P. J. Bastian, L. A. Mangold, J. I. Epstein, A. W. Partin, Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101, 2001-2005 (2004).
39. J. I. Epstein, P. C. Walsh, M. Carmichael, C. B. Brendler, Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271, 368-374 (1994).
40. W. Siu, R. L. Dunn, R. B. Shah, J. T. Wei, Use of extended pattern technique for initial prostate biopsy. J. Urol. 174, 505-509 (2005).
41. E. L. Lehmann, H. J. M. D'Abrera, Nonparametrics: Statistical Methods Based on Ranks (Holden-Day, San Francisco, CA, 1975), p. xvi.
42. E. R. DeLong, D. M. DeLong, D. L. Clarke-Pearson, Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44, 837-845 (1988).
43. Funding: Supported in part by Gen-Probe Inc., the Early Detection Research Network (U01CA111275 and U01 CA113913), NIH SPORE (P50 CA69568), and R01 CA132874. S.A.T. is supported by a Young Investigator Award from the Prostate Cancer Foundation. A.M.C. is supported by the Burroughs Wellcome Fund, the Doris Duke Foundation, and the Prostate Cancer Foundation. Author contributions: S.A.T. and A.M.C. had full access to all thedata in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. S.A.T., S.M.J.A., A.B., Y.P., M.G.S., M.A.R., D.R.R., H.R., J.G., J.T.W., and A.M.C. designed the study. S.M.J.A., S. Miick, J.R.D., S.W., P.H., J.M., H.R., and J.G. developed and performed the TMA assays. J.L.S., L.S.-M., D.W., B. Hollenbeck, K.S., J.S., Y.F., J.B.A., S. Meyers, and J.T.W. obtained, evaluated, and processed specimens. R.V. maintained clinical information. B. Han, L.W., and N.P. performed FISH assays. S.A.T. and R.J.L. analyzed the data. S.A.T. wrote the first draft of the manuscript, which was reviewed by all authors. Competing interests: The University of Michigan and Brigham and Women's Hospital have been issued a patent on the detection of ETS gene fusions in prostate cancer, on which S.A.T., M.A.R., D.R.R., and A.M.C. are listed as coinventors. The diagnostic field of use has been licensed to Gen-Probe. A.M.C. and J.T.W. have served as consultants for Gen-Probe. Gen-Probe has provided material support for a clinical trial evaluating PCA3, on which J.T.W. is the primary investigator. Y.F. is cofounder of Diagnocure, which licensed diagnostic rights to the PCA3 gene to Gen-Probe. J.S. and M.A.R. have received honoraria from Gen-Probe. M.G.S. has received research funding from Beckman-Coulter and Source-MDx. S.M.J.A., S. Miick, S.W., P.H., J.M., J.R.D., A.B., Y.P., H.R., and J.G. are employees of Gen-Probe. The remaining authors declare no conflicts of interest.